cyrilzakka/clinical-trials huggingface dataset:
Study for the Employment Retention of Veterans

The Study for Employment Retention of Veterans (SERVe) is a randomized controlled trial, available exclusively to Oregon employers of veterans. It is designed to develop and scientifically evaluate Veteran-supportive supervisor training (VSST) that may enhance retention of veterans, with the goal of improving workplace culture and general well-being to our service members. The intervention, applied to workplace supervisors, will be measured by experience of veterans, assessing workplace experiences, health, well-being, as well as employees' spouse/partners' family experiences, health and well-being, and workplace outcomes.

The overall goal of the Study for Employment Retention of Veterans (SERVe) study is to improve health and well-being of current and former service members employed in participating Oregon organizations. The SERVe Study seeks to do this by training supervisors to support veteran employees by focusing on a reduction in work-life stress while increasing supportive supervisor behavior.

The SERVe Study proposes that supervisor supportiveness can influence workplace experience, health, and well-being of service members, as well as of their families.

The investigators of the SERVe Study expect positive results for study participants, including reduced stress and increased social support, reduction in negative workplace experiences, and improvement in family well-being outcomes. Longer term, these effects are expected to create a more supportive work environment, which has positive effects on safety, health, well-being, family, and organizational outcomes.

Veteran participants are measured at baseline, three months, and nine months. Veteran spouses are invited to participate as well. Married and cohabitating veterans and their partners are invited to participate in the Daily Family Study (DFS), a 32-day daily diary survey after baseline and at six months.

Eligibility Criteria:
Inclusion Criteria:

* Must have served in the United States Armed Forces since September, 2001
* Must work at least 20 hours per week at a participating organization

Exclusion Criteria:

-
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).


Eligibility Criteria:
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
* Life expectancy of at least 12 weeks
* Histologic documentation of adenocarcinoma of the prostate
* Surgical castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed castrate levels of testosterone
* Metastatic progressive CRPC defined as progressive disease despite surgical castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed castrate levels of testosterone
* For patients in the dose-expansion cohort of the study, not more than two prior lines of cytotoxic chemotherapy in the metastatic setting
* Evaluable or measurable disease
* Documented willingness to use an effective means of contraception

Exclusion Criteria:

* Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy, or radiotherapy within 4 weeks prior to Day 1, with the following exceptions: maintenance hormonal therapy for metastatic prostate cancer and palliative radiation to bone metastases within 2 weeks prior to Day 1
* Major surgical procedure within 4 weeks prior to Day 1
* Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infections of the nail beds)
* Ongoing corticosteroid use with \> 10 mg of daily prednisone or equivalent
* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.
* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
* Untreated or active central nervous system (CNS) metastases. Patients with a history of treated CNS metastases are eligible, provided that they meet all of the following criteria: evaluable or measurable disease outside the CNS, radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study, and screening CNS radiographic study is \>/= 8 weeks since completion of radiotherapy and \>/= 4 weeks since the discontinuation of corticosteroids and anticonvulsants
* Dose expansion cohort (B): no prior chemotherapy is allowed
Attention Control Treatment for Post Traumatic Stress Disorder ׂ(PTSD)

The purpose of this study is to explore the efficacy of Attention Control Training for Post Traumatic Stress Disorder (PTSD).

ACT was found to be effective in decreasing attention bias variability and PTSD symptoms in combat veterans (Badura-Brack, et al., 2015). It is now important to continue the examination of ACT's efficacy in additional populations of patients with PTSD. Such extension of treatment to other traumatic experiences raises the question of whether the threatening content of the training material could be personalized for each patient.

The aim of this study is to explore the efficacy of Attention Control Training for Post Traumatic Stress Disorder (PTSD).

ACT was found to be effective in decreasing attention bias variability and PTSD symptoms in combat veterans (Badura-Brack, et al., 2015). It is now important to continue the examination of ACT's efficacy in additional populations of patients with PTSD. Such extension of treatment to other traumatic experiences raises the question of whether the threatening content of the training material could be personalized for each patient.

For this purpose, we will recruit participants that are diagnosed with PTSD and will be randomly assigned to one of three conditions: personalized ACT, non-personalized ACT, or control training We expect that personalized ACT will produce greater reduction in PTSD symptoms relative to a non-personalized ACT, and that both these conditions will be more effective in symptoms reduction than a control condition not designed to affect attention or expose patients to threat stimuli. We also expect the ACT conditions to reduce attention bias variability relative to the control condition.

Eligibility Criteria:
Inclusion Criteria:

Meeting a current diagnosis of Post-Traumatic Stress Disorder (PTSD) according to DSM-V (American Psychiatric Association, 2013);

Exclusion Criteria:

1. A diagnosis of psychotic or bipolar disorders.
2. A diagnosis of a neurological disorder (i.e., epilepsy, brain injury).
3. Suicidal ideation.
4. Drugs or alcohol abuse.
5. Non-fluent Hebrew.
6. A pharmacological treatment that is not stabilized in the past 3 months (a stable treatment will not be a reason for exclusion from the study).
7. Pregnancy. -
Paravertebral Catheters for VATS Procedures

Level I randomized prospective outcomes study comparing two groups of patients. One group will receive Dilaudid patient controlled analgesia (PCA) post-operatively. The other will receive an ultrasound guided paravertebral block with indwelling paravertebral catheter with an infusion of 0.2% Ropivicaine post-operatively and a PCA.

Design: Level I randomized prospective outcomes study comparing two groups of patients. One group will receive Dilaudid patient controlled analgesia (PCA) post-operatively. The other will receive an ultrasound guided paravertebral block with indwelling paravertebral catheter with an infusion of 0.2% Ropivicaine post-operatively and a PCA.

Sample Size: 50 patients Study Duration: Approximately 24 months Population:. Patients presenting to the University of Minnesota Medical Center for elective Video Assisted Thoracoscopic Surgery (VATS), for thoracic, lung, or mediastinal lesions or masses.

Primary Objective: To determine if post-operative paravertebral catheters in patients with elective VATS procedures result in decreased pain compared to patients treated with PCA for post-operative pain.

Secondary Objectives:

1. To determine whether the use of paravertebral catheters impacts the length of ICU and hospital stay for patients, compared to a PCA in patients undergoing elective Video Assisted Thoracoscopic Surgery (VATS).
2. To determine whether the use of paravertebral catheters leads to lower risk of complications, compared to use of a PCA in patients undergoing elective Video Assisted Thoracoscopic Surgery (VATS).

2. Synopsis and Medical Application:

Specific Aims:

Primary Hypothesis: Paravertebral catheters will result in improved pain control relative to PCA for post-operative pain from thoracic surgery.

Secondary Hypothesis: Paravertebral catheters will result in fewer hospital days and improved subjective respiratory function compared to patients in the PCA group.

Eligibility Criteria:
Inclusion Criteria:

* • All patients undergoing elective VATS.

Exclusion Criteria:

* • Previous difficult airway or multiple previous intubations

  * History of myasthenic syndrome
  * Systemic infection
  * Pre-existing sensory deficit
  * PT \>14 or PTT \>40 sec
  * Platelet count less than 50,000
  * Creatinine \> 1.5
  * Allergy to local anesthetics
  * Patients who remain intubated for one week after surgery or who are unable to provide information as to their feelings of pain post-operatively for the first week post-operatively
  * Use of a spinal or epidural anesthetic for surgery
  * Daily use of opioid for more than a week
  * Lack of patient cooperation
  * Contraindication to regional anesthesia

    * Infection at injection site
    * Inability to guarantee sterile equipment or sterile conditions for the block
    * Patient refusal
    * Risk of local anesthetic toxicity
    * Coagulopathy or bleeding disorder
    * Severe respiratory disease (where the patient depends on intercostal muscle function for ventilation);
    * Ipsilateral diaphragmatic paresis;
    * Severe spinal deformities (kyphosis or scoliosis)
    * Previous thoracotomy
CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.


Eligibility Criteria:
Inclusion Criteria:

* It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form.

Exclusion Criteria:

* Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).

This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).A total of 236 patients will be randomized in a 1:1 ratio into the immediate transplantation group (n=118) and the disease control group (n=118). The study will continue until at least 124 events occur.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years
2. High relapse risk MDS, defined by:

   * IPSS-R score ≥3.5.
   * IPSS-M stratification as intermediate-high, high, or very high risk.
3. Eligible for allogeneic HSCT (including matched or mismatched related/unrelated donor transplantations).
4. Karnofsky Performance Status (KPS) ≥60.
5. Signed informed consent.

Exclusion Criteria:

1. Severe organ dysfunction:

   * Left ventricular ejection fraction \<50%.
   * Oxygen supplementation requirement.
   * Serum bilirubin \>1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT \>5x upper limit of normal.
   * Estimated glomerular filtration rate (eGFR) \<50 mL/min.
2. History of prior allogeneic HSCT.
3. Any condition deemed unsuitable by the investigator.
Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

The purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of atopic dermatitis. The investigators also aim to determine the effects of this online care model on patient quality of life as well as patient and physician satisfaction.

The investigators' hypotheses include the following:

1. Compared to in-person visits, the online care model will result in similar clinical improvement in atopic dermatitis disease severity.
2. Compared to in-person visits, the online care model will result in similar improvements in quality of life.
3. Providers and subjects in the online group will achieve a similar level of overall satisfaction as those in the in-person group.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 4 years or older at time of consent, may be male or female.
* Meet the Hanifin diagnostic criteria for atopic dermatitis.
* Capable of giving informed consent (for patients less than 18 years of age, assent will be obtained from the minor and informed consent will be obtained from a legal guardian).
* Able to image their skin or have someone do it for them.
* Able to adhere to the study visit schedule and other protocol requirements.
* Have access to a computer with internet connection, a digital camera, and an e-mail address.

Exclusion Criteria:

* Non English speaking patients.
* Patients requiring systemic treatment (e.g., cyclosporine, phototherapy).
* Patients requiring close laboratory monitoring.
Point of Care Rapid STI Test Optimization and Validation Extension

The purpose of this sub-study (PROVE) is to support and facilitate the validation of commercially available point of care (POC) sexually transmitted infection (STI) diagnostic test kits/devices for potential on-site laboratory use as well as bedside use in parallel to gold standard established testing methodologies. A further extension of bedside testing would include self-testing.

Screening and Enrolment procedures for the ARISE study (HREC Ref No. 210614) involves adolescent girls and young women (AGYW) being screened for Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) as determined through testing of clinician-collected genital swabs followed by GeneXpert, OSOM rapid TV testing or through wet mount visualisation of the micro-organisms of interest. This will generate a pool of AGYW with known STI diagnoses who, if positive, will be treated on-site on the day of STI detection. It will also create an ideal opportunity to leverage access to samples from willing participants (prior to STI treatment if STI positive) for validation of a range of alternate STI test kits. Samples provided will enable same-day parallel testing on additional platforms for validation of the sensitivity and specificity of these alternate tests against the known validated platformsThis initiative will expand the menu of cost effective and user friendly STI test kits that may ultimately be used in other research studies, in public clinic settings and as self-tests performed discretely in the convenience and privacy of one's home.

Eligibility Criteria:
Inclusion Criteria:

Participants must meet the following criteria to be eligible for inclusion in the study:

* Cisgender adolescent girls and young women (18-25 years of age, inclusive), screened for or enrolled in the ARISE study.
* Willing to provide written informed consent to participate in this sub-study.
* Willing to provide additional samples including vaginal and endocervical swabs, urine and those collected through the use of tampons and disposable menstrual cups.

Exclusion Criteria:

* Cisgender male or transgender woman or transgender man
* Age \<18 years
* Unable or unwilling to provide written informed consent
* Have any condition that in the opinion of the investigators will interfere with successful completion of sub-study procedures
Urgent Care for the Elderly: Impairment and Home Care Services

Elderly population is increasing quickly and their need for health care ressources through emergency care is also growing. While these patients are ageing physical impairment often happens along the way. Apart from senior homes, different types and levels of home care services have been developped in order to overcome or to adapt to these situations.

Our goals are:

* to assess mortality rate depending on home care services level for the elderly population consulting in the ED or being taken in charge by the Emergency Medical System in France.
* to describe this population in terms of autonomy, impairment and home care services


Eligibility Criteria:
Inclusion Criteria:

* patients aged 80 and over

Exclusion Criteria:

* aged\<80 years old
Case-Control Study to Identify Risk Factors for Microscopic Colitis

The purpose of the study is to assess among others environmental and hygiene-related risk factors for microscopic colitis (MC), a common diarrheal disease.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed Diagnosis of MC (CC or LC) between January 1, 2000 and December 31, 2012.
* Inhabitant of the province of Limburg or the Eindhoven region at the moment of diagnosis

Exclusion Criteria:

* Below 18 years of age at the time of diagnosis
* Not capable of signing an informed consent
* Deceased at moment of approximation
Role of Methylene Blue in Parotid Surgery

usefulness of the methylene blue staining for identification of facial nerve in parotid gland surgery

The specific surgical morbidity remains significant in parotid gland surgery. In addition to temporary facial weakness and permanent facial nerve injury, postparotidectomy depression and Frey's syndrome (gustatory sweating) are specific for this type of surgery. To reduce the surgical morbidity, several modifications of parotidectomy have been implemented but postsurgical complications remain especially facial nerve injury . To overcome this difficulty, an identification method might be used such as preoperative intravital staining of the gland with methylene blue (MB).

Although MB staining is not designed to be used as a sole technique, it can be combined with other techniques such as identification of the anatomic landmarks. MB staining is simple, inexpensive, and not time consuming technique.It is an indirect facial nerve identification technique, because there is no nerve handling,thus decreasing iatrogenic nerve impairment.After injection of the parotid gland with MB dye, fine white nerve fibers can be observed . Tumors in the parotid gland are also easily seen because they are not stained and will be visible in the surgical field.

Eligibility Criteria:
Inclusion Criteria:

* All new cases presented with primary benign or malignant parotid tumors.

Exclusion Criteria:

* Cases with secondary tumors of the gland
Individual Versus Group-based Exercise Rehabilitation for Shoulder Disorders: a Randomised Controlled Trial

Degenerative shoulder disorders are frequent in the Danish population and often cause disability and sick leave. After hospital discharge patients are often referred to physiotherapy rehabilitation as part of the treatment, and it is often assumed that one-on-one sessions will yield better results than group-based sessions, because individual needs can be better meet and targeted

The project aims to evaluate the effect and cost-effectiveness of group- based exercise rehabilitation as compared to individual exercise rehabilitation in patients with degenerative shoulder disorders.

.

The study is a three-armed controlled randomized trial in which a total of 180 patients referred to the municipal rehabilitation after hospital treatment due to shoulder disorders in 6 municipalities in Region Midtjylland expected to participate. Patients will be allocated to either 1) Group-based rehabilitation 2) Individual rehabilitation or 3) Home exercise.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and above, ability to speak and understand Danish and referred to physiotherapy rehabilitation after hospital conservative or surgical treatment under diagnose of rotator cuff/shoulder impingement or acromioclavicular osteoarthritis (International Classification of Diseases 10th revision \[ICD-10\] group M75.1-M75.8, M19.8).

Exclusion Criteria:

* Influence of co-morbidity, psychiatric illness, pregnancy, fullthickness rotator cuff tear, rotator cuff repair surgery, traumatic lesion, rheumatoid arthritis, frozen shoulder, glenohumeral osteoarthritis.